Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 9.24 is 12% below its 5-year average of 10.47, near the low end of its 5-year range (6.05–17.69).
As of the fiscal period ended Tuesday, June 30, 2026. 30.43% above its 12-month average of 7.09.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 9.24.
CURRENT RATIO
9.24
CURRENT RATIO AVG TTM
7.09
CURRENT RATIO AVG 3Y
8.34
CURRENT RATIO AVG 5Y
10.47
CURRENT RATIO AVG 10Y
13.81
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+30.43%
CURRENT VS 3Y AVG
+10.80%
CURRENT VS 5Y AVG
-11.73%
CURRENT VS 10Y AVG
-33.08%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+146.53%
vs the sector median at left
Rocket Pharmaceuticals, Inc.
Market Cap
$271.35M
Current Ratio
9.24
TTM Avg
7.09
3Y Avg
8.34
5Y Avg
10.47
Market Cap
$271.00M
Current Ratio
4.85
TTM Avg
6.69
3Y Avg
6.56
5Y Avg
6.64
Market Cap
$270.31M
Current Ratio
1.61
TTM Avg
3.39
3Y Avg
4.35
5Y Avg
5.01
Market Cap
$270.68M
Current Ratio
9.22
TTM Avg
6.22
3Y Avg
4.84
5Y Avg
4.06
Market Cap
$272.77M
Current Ratio
5.35
TTM Avg
2.41
3Y Avg
1.69
5Y Avg
2.06
Market Cap
$267.60M
Current Ratio
2.90
TTM Avg
4.46
3Y Avg
4.43
5Y Avg
4.81
Market Cap
$264.52M
Current Ratio
4.50
TTM Avg
8.35
3Y Avg
6.79
5Y Avg
6.91
Market Cap
$264.73M
Current Ratio
15.82
TTM Avg
24.04
3Y Avg
14.70
5Y Avg
12.06
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rocket Pharmaceuticals, Inc. (RCKT) | $271.35M | 9.24 | 7.09 | 8.34 | 10.47 |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | 4.85 | 6.69 | 6.56 | 6.64 |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | 1.61 | 3.39 | 4.35 | 5.01 |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.68M | 9.22 | 6.22 | 4.84 | 4.06 |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $272.77M | 5.35 | 2.41 | 1.69 | 2.06 |
| Scribe Therapeutics Inc. (SCTX)vs › | $272.51M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $267.60M | 2.90 | 4.46 | 4.43 | 4.81 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.52M | 4.50 | 8.35 | 6.79 | 6.91 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | 15.82 | 24.04 | 14.70 | 12.06 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $263.49M | 16.00 | 13.11 | 8.33 | 7.81 |
Current Ratio
9.24
Quick Ratio
9.24
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 9.24 |
| 2026-03-31 | 6.12 |
| 2025-12-31 | 6.38 |
| 2025-09-30 | 7.30 |
| 2025-06-30 | 6.39 |
| 2025-03-31 | 9.19 |
| 2024-12-31 | 9.30 |
| 2024-09-30 | 6.05 |
| 2024-06-30 | 7.79 |
| 2024-03-31 | 10.47 |
| 2023-12-31 | 7.80 |
| 2023-09-30 | 13.35 |
| 2023-06-30 | 9.09 |
| 2023-03-31 | 10.83 |
| 2022-12-31 | 9.29 |
| 2022-09-30 | 10.31 |
| 2022-06-30 | 13.41 |
| 2022-03-31 | 15.68 |
| 2021-12-31 | 17.69 |
| 2021-09-30 | 17.36 |
| 2021-06-30 | 16.92 |
| 2021-03-31 | 11.65 |
| 2020-12-31 | 14.94 |
| 2020-09-30 | 7.30 |
| 2020-06-30 | 12.35 |
| 2020-03-31 | 13.25 |
| 2019-12-31 | 16.81 |
| 2019-09-30 | 11.07 |
| 2019-06-30 | 17.48 |
| 2019-03-31 | 9.70 |
| 2018-12-31 | 13.60 |
| 2018-09-30 | 12.51 |
| 2018-06-30 | 13.27 |
| 2018-03-31 | 25.19 |
| 2017-12-31 | 24.83 |
| 2017-09-30 | 27.57 |
| 2017-06-30 | 27.35 |
| 2017-03-31 | 22.14 |
| 2016-12-31 | 17.80 |
| 2016-09-30 | 23.37 |
| 2016-06-30 | 24.25 |
| 2016-03-31 | 22.38 |
| 2015-12-31 | 27.13 |
| 2015-09-30 | 36.76 |
| 2015-06-30 | 20.18 |
| 2015-03-31 | 21.75 |
| 2014-12-31 | 0.51 |
| 2014-09-30 | 1.35 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
| 2013-12-31 | 4.00 |
